Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
| ANNX Stock | USD 5.14 0.03 0.58% |
Slightly above 61% of Annexon's investor base is looking to short. The analysis of the overall investor sentiment regarding Annexon suggests that many traders are alarmed. Annexon's investing sentiment can be driven by a variety of factors including economic data, Annexon's earnings reports, geopolitical events, and overall market trends.
Annexon |
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral...
Read at globenewswire.com
 |
Annexon Fundamental Analysis
We analyze Annexon's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Annexon using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Annexon based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Annexon is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Annexon Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Annexon stock to make a market-neutral strategy. Peer analysis of Annexon could also be used in its relative valuation, which is a method of valuing Annexon by comparing valuation metrics with similar companies.
Peers
Annexon Related Equities
| GPCR | Structure Therapeutics | 11.00 | ||||
| IMMX | Immix Biopharma | 6.55 | ||||
| INZY | Inozyme Pharma | 4.46 | ||||
| RCUS | Arcus Biosciences | 2.94 | ||||
| DAWN | Day One | 2.85 | ||||
| CGEM | Cullinan Oncology | 2.62 | ||||
| ABOS | Acumen Pharmaceuticals | 2.60 | ||||
| RLAY | Relay Therapeutics | 2.37 | ||||
| AMLX | Amylyx Pharmaceuticals | 1.54 | ||||
| WVE | Wave Life | 0.56 | ||||
| BPMC | Blueprint Medicines | 2.56 | ||||
| INAB | In8bio | 3.03 | ||||
| HEPA | Hepion Pharmaceuticals | 4.35 | ||||
| ZURA | Zura Bio | 6.83 | ||||
| CNSP | Cns Pharmaceuticals | 7.69 | ||||
| XFOR | X4 Pharmaceuticals | 8.11 |
Additional Tools for Annexon Stock Analysis
When running Annexon's price analysis, check to measure Annexon's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexon is operating at the current time. Most of Annexon's value examination focuses on studying past and present price action to predict the probability of Annexon's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexon's price. Additionally, you may evaluate how the addition of Annexon to your portfolios can decrease your overall portfolio volatility.